{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:32:39Z","timestamp":1791250359545,"version":"4.1.0"},"reference-count":49,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Epidermal growth factor receptor (EGFR) pathway activation causes chemotherapy resistance, and inhibition of the EGFR pathway sensitizes triple-negative breast cancer (TNBC) cells to chemotherapy in preclinical models. Given the high prevalence of EGFR overexpression in TNBC, we conducted a single-arm phase II study of panitumumab (anti-EGFR monoclonal antibody), carboplatin, and paclitaxel as the second phase of neoadjuvant therapy (NAT) in patients with doxorubicin and cyclophosphamide (AC)\u2013resistant TNBC (NCT02593175).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Patients with early-stage, AC-resistant TNBC, defined as disease progression or \u226480% reduction in tumor volume after four cycles of AC, were eligible for this study and received panitumumab (2.5 mg\/kg i.v., every week \u00d7 13), paclitaxel (80 mg\/m2 i.v. every week \u00d7 12), and carboplatin (AUC = 4 i.v., every 3 weeks \u00d7 4) as the second phase of NAT. A two-stage Gehan-type design was used to detect an improvement in the pathological complete response (pCR)\/residual cancer burden class I (RCB-I) rate from 5% to 20%. Whole-exome sequencing was performed on diagnostic tumor biospecimens, where available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>From November 3, 2016, through August 23, 2021, 43 patients with AC-resistant TNBC were enrolled. The combined pCR\/RCB-I rate was 30.2%. The most common treatment-related adverse events were neutropenia (72%) and anemia (61%), with 7 (16%), 16 (37%), and 8 (19%) patients experiencing grade 4 neutropenia, grade 3 neutropenia, and grade 3 anemia, respectively. No new safety signals were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study met its primary endpoint (pCR\/RCB-I = 30.2% vs. 5% in historical controls), suggesting that panitumumab should be evaluated as a component of NAT in patients with chemotherapy-resistant TNBC in a larger, randomized clinical trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The epidermal growth factor receptor (EGFR) pathway has been implicated as a driver of chemotherapy resistance in triple-negative breast cancer (TNBC). Here, we evaluate the combination of panitumumab, carboplatin, and paclitaxel as the second phase of neoadjuvant therapy (NAT) in patients with AC-resistant TNBC. This study met its primary efficacy endpoint, and molecular alterations in EGFR pathway genes did not seem to influence response to the study regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0255","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T08:27:44Z","timestamp":1727857664000},"page":"2823-2834","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0809-0851","authenticated-orcid":false,"given":"Clinton","family":"Yam","sequence":"first","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0942-2731","authenticated-orcid":false,"given":"Miral","family":"Patel","sequence":"additional","affiliation":[{"name":"2Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3642-1897","authenticated-orcid":false,"given":"Holly A.","family":"Hill","sequence":"additional","affiliation":[{"name":"3Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1176-1561","authenticated-orcid":false,"given":"Ryan","family":"Sun","sequence":"additional","affiliation":[{"name":"4Division of Basic Sciences, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4534-2042","authenticated-orcid":false,"suffix":"Jr","given":"Roland L.","family":"Bassett","sequence":"additional","affiliation":[{"name":"4Division of Basic Sciences, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9199-1537","authenticated-orcid":false,"given":"Elisabeth","family":"Kong","sequence":"additional","affiliation":[{"name":"3Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2470-0891","authenticated-orcid":false,"given":"Senthil","family":"Damodaran","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0610-5853","authenticated-orcid":false,"given":"Kimberly B.","family":"Koenig","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8366-1274","authenticated-orcid":false,"given":"Sausan","family":"Abouharb","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8731-2573","authenticated-orcid":false,"given":"Sadia","family":"Saleem","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3177-3853","authenticated-orcid":false,"given":"Ajit K.","family":"Bisen","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0103-4718","authenticated-orcid":false,"given":"Rashmi K.","family":"Murthy","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2992-6803","authenticated-orcid":false,"given":"David L.","family":"Ramirez","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2079-5202","authenticated-orcid":false,"given":"Gaiane M.","family":"Rauch","sequence":"additional","affiliation":[{"name":"2Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5539-5332","authenticated-orcid":false,"given":"Beatriz E.","family":"Adrada","sequence":"additional","affiliation":[{"name":"2Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7897-7896","authenticated-orcid":false,"given":"Rosalind P.","family":"Candelaria","sequence":"additional","affiliation":[{"name":"2Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4511-8638","authenticated-orcid":false,"given":"Xiaoping","family":"Wang","sequence":"additional","affiliation":[{"name":"5Cancer Biology and Therapeutic Program, University of Hawai\u2019i Cancer Center, Honolulu, Hawaii."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9762-8536","authenticated-orcid":false,"given":"Elizabeth A.","family":"Mittendorf","sequence":"additional","affiliation":[{"name":"6Division of Breast Surgery, Department of Surgery, Brigham and Women\u2019s Hospital, Boston, Massachusetts."},{"name":"7Breast Oncology Program, Dana-Farber\/Brigham Cancer Center, Boston, Massachusetts."},{"name":"8Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0604-7267","authenticated-orcid":false,"given":"Alastair M.","family":"Thompson","sequence":"additional","affiliation":[{"name":"9Division of Surgical Oncology, Section of Breast Surgery, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7140-545X","authenticated-orcid":false,"given":"Jason B.","family":"White","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3972-1118","authenticated-orcid":false,"given":"Elizabeth E.","family":"Ravenberg","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1628-3331","authenticated-orcid":false,"given":"Alyson R.","family":"Clayborn","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8974-2419","authenticated-orcid":false,"given":"Qing-Qing","family":"Ding","sequence":"additional","affiliation":[{"name":"10Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6987-7115","authenticated-orcid":false,"given":"Daniel J.","family":"Booser","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0464-8317","authenticated-orcid":false,"given":"Oluchi","family":"Oke","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3024-3244","authenticated-orcid":false,"given":"Abenaa M.","family":"Brewster","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4873-4412","authenticated-orcid":false,"given":"Gabriel N.","family":"Hortobagyi","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8660-243X","authenticated-orcid":false,"given":"Nuhad K.","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8390-4985","authenticated-orcid":false,"given":"Jennifer K.","family":"Litton","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5913-7480","authenticated-orcid":false,"given":"Vicente","family":"Valero","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5475-8509","authenticated-orcid":false,"given":"Banu K.","family":"Arun","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5711-2404","authenticated-orcid":false,"given":"Debu","family":"Tripathy","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4578-5636","authenticated-orcid":false,"given":"Jeffrey T.","family":"Chang","sequence":"additional","affiliation":[{"name":"11Department of Integrative Biology and Pharmacology, McGovern Medical School, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4013-5279","authenticated-orcid":false,"given":"Ken","family":"Chen","sequence":"additional","affiliation":[{"name":"3Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8072-9026","authenticated-orcid":false,"given":"Anil","family":"Korkut","sequence":"additional","affiliation":[{"name":"3Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6078-2769","authenticated-orcid":false,"given":"Stacy L.","family":"Moulder","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7533-9082","authenticated-orcid":false,"given":"Lei","family":"Huo","sequence":"additional","affiliation":[{"name":"10Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4182-6058","authenticated-orcid":false,"given":"Bora","family":"Lim","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0166-7275","authenticated-orcid":false,"given":"Naoto T.","family":"Ueno","sequence":"additional","affiliation":[{"name":"1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"2025040317272046600_bib1","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","article-title":"Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype","volume":"35","author":"Symmans","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025040317272046600_bib2","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"2025040317272046600_bib3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"2025040317272046600_bib4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","article-title":"Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522","volume":"35","author":"Pusztai","year":"2024","journal-title":"Ann Oncol"},{"key":"2025040317272046600_bib5","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1146\/annurev.biochem.68.1.965","article-title":"AKT\/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation","volume":"68","author":"Chan","year":"1999","journal-title":"Annu Rev Biochem"},{"key":"2025040317272046600_bib6","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/annonc\/mdn710","article-title":"Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer","volume":"20","author":"Corkery","year":"2009","journal-title":"Ann Oncol"},{"key":"2025040317272046600_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10549-007-9756-8","article-title":"Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients","volume":"111","author":"Tan","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"2025040317272046600_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.22381","article-title":"Prognostic markers in triple-negative breast cancer","volume":"109","author":"Rakha","year":"2007","journal-title":"Cancer"},{"key":"2025040317272046600_bib9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1075-122X.2006.00276.x","article-title":"The challenging estrogen receptor-negative\/progesterone receptor-negative\/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy?","volume":"12","author":"Siziopikou","year":"2006","journal-title":"Breast J"},{"key":"2025040317272046600_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.biochi.2014.06.011","article-title":"Epidermal growth factor\/heat shock protein 27 pathway regulates vasculogenic mimicry activity of breast cancer stem\/progenitor cells","volume":"104","author":"Lee","year":"2014","journal-title":"Biochimie"},{"key":"2025040317272046600_bib11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12032-014-0275-2","article-title":"Correlation between epidermal growth factor receptor and tumor stem cell markers CD44\/CD24 and their relationship with prognosis in breast invasive ductal carcinoma","volume":"32","author":"Zheng","year":"2015","journal-title":"Med Oncol"},{"key":"2025040317272046600_bib12","doi-asserted-by":"crossref","first-page":"e75907","DOI":"10.1371\/journal.pone.0075907","article-title":"Distinct effects of EGFR ligands on human mammary epithelial cell differentiation","volume":"8","author":"Mukhopadhyay","year":"2013","journal-title":"PLoS One"},{"key":"2025040317272046600_bib13","doi-asserted-by":"crossref","first-page":"67904","DOI":"10.18632\/oncotarget.18958","article-title":"EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"2025040317272046600_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10549-012-2289-9","article-title":"Role of epidermal growth factor receptor in breast cancer","volume":"136","author":"Masuda","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2025040317272046600_bib15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/307521a0","article-title":"Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences","volume":"307","author":"Downward","year":"1984","journal-title":"Nature"},{"key":"2025040317272046600_bib16","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1002\/j.1460-2075.1995.tb00101.x","article-title":"Heregulin-dependent regulation of HER2\/neu oncogenic signaling by heterodimerization with HER3","volume":"14","author":"Wallasch","year":"1995","journal-title":"EMBO J"},{"key":"2025040317272046600_bib17","first-page":"1813","article-title":"Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas","volume":"10","author":"Alimandi","year":"1995","journal-title":"Oncogene"},{"key":"2025040317272046600_bib18","doi-asserted-by":"crossref","first-page":"2005.0008","DOI":"10.1038\/msb4100012","article-title":"Phosphotyrosine interactome of the ErbB-receptor kinase family","volume":"1","author":"Schulze","year":"2005","journal-title":"Mol Syst Biol"},{"key":"2025040317272046600_bib19","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1158\/1078-0432.CCR-09-0951","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer","volume":"15","author":"Zhang","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2025040317272046600_bib20","doi-asserted-by":"crossref","first-page":"eabn7983","DOI":"10.1126\/sciadv.abn7983","article-title":"EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer","volume":"8","author":"Wang","year":"2022","journal-title":"Sci Adv"},{"key":"2025040317272046600_bib21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10549-008-0206-z","article-title":"Invasive ductal carcinoma of the breast with the [L8D2Q2M0]triple-negative[R8D2Q2M1] phenotype: prognostic implications of EGFR immunoreactivity","volume":"116","author":"Viale","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"2025040317272046600_bib22","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2012.03.031","article-title":"Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks","volume":"149","author":"Lee","year":"2012","journal-title":"Cell"},{"key":"2025040317272046600_bib23","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/jnci\/85.16.1327","article-title":"Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies","volume":"85","author":"Baselga","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"2025040317272046600_bib24","first-page":"1236","article-title":"Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy","volume":"59","author":"Yang","year":"1999","journal-title":"Cancer Res"},{"key":"2025040317272046600_bib25","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1001\/jamaoncol.2018.1436","article-title":"Safety and efficacy of panitumumab plus neoadjuvant chemotherapy in patients with primary HER2-negative inflammatory breast cancer","volume":"4","author":"Matsuda","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025040317272046600_bib26","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/annonc\/mdu183","article-title":"Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline\/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact","volume":"25","author":"Nabholtz","year":"2014","journal-title":"Ann Oncol"},{"key":"2025040317272046600_bib27","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1080\/15384047.2015.1026481","article-title":"A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer","volume":"16","author":"Cowherd","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"2025040317272046600_bib28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.clbc.2016.05.006","article-title":"Panitumumab, gemcitabine, and carboplatin as treatment for women with metastatic triple-negative breast cancer: a sarah cannon research Institute phase II trial","volume":"16","author":"Yardley","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"2025040317272046600_bib29","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"2025040317272046600_bib30","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025040317272046600_bib31","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"2025040317272046600_bib32","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1158\/1078-0432.CCR-21-0144","article-title":"Immune phenotype and response to neoadjuvant therapy in triple-negative breast cancer","volume":"27","author":"Yam","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025040317272046600_bib33","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1158\/1078-0432.CCR-21-3100","article-title":"Molecular characterization and prospective evaluation of pathologic response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer","volume":"28","author":"Yam","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025040317272046600_bib34","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3390\/cancers14051323","article-title":"Prognostic impact of high baseline stromal tumor-infiltrating lymphocytes in the absence of pathologic complete response in early-stage triple-negative breast cancer","volume":"14","author":"Abuhadra","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"Suppl 15","key":"2025040317272046600_bib35","doi-asserted-by":"crossref","first-page":"e14589","DOI":"10.1200\/JCO.2017.35.15_suppl.e14589","article-title":"Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx","volume":"35","author":"Kulangara","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025040317272046600_bib36","doi-asserted-by":"crossref","first-page":"11.10.1","DOI":"10.1002\/0471250953.bi1110s43","article-title":"From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline","volume":"43","author":"Van der Auwera","year":"2013","journal-title":"Curr Protoc Bioinformatics"},{"key":"2025040317272046600_bib37","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2025040317272046600_bib38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","article-title":"Genomic and molecular landscape of DNA damage repair deficiency across the Cancer Genome Atlas","volume":"23","author":"Knijnenburg","year":"2018","journal-title":"Cell Rep"},{"key":"2025040317272046600_bib39","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.gim.2022.01.001","article-title":"Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)","volume":"24","author":"Horak","year":"2022","journal-title":"Genet Med"},{"key":"2025040317272046600_bib40","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"2025040317272046600_bib41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12920-014-0064-y","article-title":"FLAGS, frequently mutated genes in public exomes","volume":"7","author":"Shyr","year":"2014","journal-title":"BMC Med Genomics"},{"key":"2025040317272046600_bib42","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res"},{"key":"2025040317272046600_bib43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2025040317272046600_bib44","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq\u2013a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics"},{"key":"2025040317272046600_bib45","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/bioinformatics\/btp692","article-title":"RNA-seq gene expression estimation with read mapping uncertainty","volume":"26","author":"Li","year":"2010","journal-title":"Bioinformatics"},{"key":"2025040317272046600_bib46","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/jnci\/djn085","article-title":"Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial","volume":"100","author":"von Minckwitz","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"2025040317272046600_bib47","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1200\/JCO.2002.20.6.1456","article-title":"Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel","volume":"20","author":"Smith","year":"2002","journal-title":"J Clin Oncol"},{"key":"2025040317272046600_bib48","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025040317272046600_bib49","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0255\/3502985\/crc-24-0255.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/10\/2823\/3512877\/crc-24-0255.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/10\/2823\/3512877\/crc-24-0255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T01:19:39Z","timestamp":1743729579000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/10\/2823\/749528\/Targeting-the-Epidermal-Growth-Factor-Receptor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0255","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.27323979","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27323976","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27323988","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727581","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727572","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727584","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727587","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727575","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27324000","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727566","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27323982","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27323991","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27324003","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27323985","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27324006","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27323997","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27323994","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27323973","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7514976","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}